3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Colorectal Neoplasms
3
Brain Neoplasms
3
Pancreatic Neoplasms
2
Breast Neoplasms
2
Warts
1
Surgical Wound
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sarcoma
1
Radiodermatitis
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuroinflammatory Diseases
1
Melanoma
1
Lung Neoplasms
1
Locally Advanced Cervical Cancer
1
Limited Stage Small Cell Lung Cancer
1
Hypoxia
1
Hemorrhage
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Atrial Fibrillation
1
Interventions
Etoposide
30
Carboplatin
29
atezolizumab
17
durvalumab
16
Cisplatin
14
Topotecan
11
Specimen Handling
9
PM 01183
9
Magnetic Resonance Spectroscopy
7
pembrolizumab
6
olaparib
5
berzosertib
4
anlotinib
4
Radiotherapy
4
Nivolumab
4
Irinotecan
4
Drug Therapy
4
tremelimumab
3
toripalimab
3
tislelizumab
3
Paclitaxel
3
Injections
3
Docetaxel
3
Biopsy
3
Bevacizumab
3
AMG 757
3
sacituzumab govitecan
2
monalizumab
2
cabozantinib
2
Temozolomide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Sodium Chloride
×
90 days
×
Clear all
NCT04624204
2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
672 enrolled